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Abstract 
 The main objective of this honor’s project is to encapsulate drugs with different molecular 
weights inside of chitosan-heparin based nanoparticles (Cs-Hep NPs). Three different drugs with 
low (NNC), medium (IFN-γ), and large (BSA) molecular weights were chosen in order to compare 
all types of drugs and how they react with the nanoparticles. Analysis of particle size, zeta 
potential, and a release study was performed. The release took place over a 168-hour time period 
and liquid samples were taken throughout. The hypothesis was that the molecular weight of the 
drug will correlate to the physical properties of the nanoparticles. 
 The results of the particle size analysis show that the largest particle size was determined 
to be interferon gamma (IFN-γ, ~2500nm), NNC-042090 (NNC, ~450nm), Nanoparticles 
(~350nm), and bovine serum albumin (BSA, ~50nm). The results of the zeta potential show that 
the encapsulated particles have a higher electro potential than empty nanoparticles. NNC released 
80% of the encapsulated drug, BSA released 70% of the encapsulated drug, while IFN-γ only 
released about 50% of the encapsulated drug. Therefore, judging from these results, the hypothesis 
partially holds true for all drugs. 
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Executive Summary 
Problem Statement 
 Drug delivery systems were first developed in the 1950s to help control the release of drugs 
ingested by the human body. This allows for a constant release rate of the drug that would 
otherwise be toxic with an uncontrolled release. Nanoparticles (NPs) are one of the best solutions 
to this problem because of their great compatibility with the human body, the amount of flexibility 
the nanoparticles present, and because of their ability to control the release of the drugs. Chitosan 
and heparin were chosen to be the main components of the nanoparticles because of chitosan’s 
ability to deliver drugs through various applications and also because of its positive surface charge. 
Heparin was chosen because of its coagulative properties and because of its overall negative 
surface charge. The synthesis of the nanoparticles involves an excess of heparin compared to the 
chitosan; therefore, it can be assumed that the nanoparticles have a net negative surface charge.  
 Three different drugs with low, medium, and large molecular weights were chosen in order 
to study the encapsulation of each drug in the nanoparticles. Using different molecular weights 
will give a good understanding of all types of drugs and how they react with the nanoparticles. In 
order to quantify the encapsulated nanoparticles, a particle size comparison, zeta potential 
comparison, and a release study was performed. The particle size comparison determines the 
average radius of each of the drugs that are encapsulated in the nanoparticles. The zeta potential 
comparison shows the difference in the electro potential between the surface of the nanoparticles 
and the surrounding fluid. This study helps show the stability and the degree of electrostatic 
repulsion between the encapsulated nanoparticles. The release study was performed three times 
for each of the three drugs in order to increase accuracy. Franz cells were placed inside of an 
incubator at 37°C to carry out the release. The release took place over a 168-hour time period and 
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liquid samples were taken every hour for the first eight hours, then every four hours until hour 32, 
then every eight hours for until hour 56, and finally every twelve hours for until hour 72. 
Results/Discussion 
 The results of the particle size analysis show that the largest particle size was determined 
to be interferon gamma (IFN-γ, ~2500nm), NNC-042090 (NNC, ~450nm), NPs (~350nm), and 
finally bovine serum albumin (BSA, ~50nm). These results are not what was expected from the 
initial hypothesis because NNC has the lowest molecular weight but has the second highest particle 
size and BSA has the highest molecular weight yet has the smallest particle size. These results 
could be due to coagulation of the particles which cause improper readings and results during 
analysis. The results of the zeta potential show that the encapsulated particles have a higher electro 
potential than empty nanoparticles. These results were expected according to the initial hypothesis.  
 The results from the release study show that all the drugs followed a general logarithmic 
trend for the release from the encapsulated nanoparticles. However, at the end of the 168-hour 
trial, NNC released 80% of the encapsulated drug, BSA released 70% of the encapsulated drug, 
while IFN-γ only released about 50% of the encapsulated drug. These results do not support the 
initial hypothesis of the dependency on the molecular weight for the released amount and release 
time. 
Conclusions 
 The initial hypothesis for this study was that there was a constant relationship between the 
release amount and release time of the encapsulated nanoparticles depending on the molecular 
weight of the chosen drug. For some instances in this study the hypothesis holds true, however for 
other instances it does not. For example, the hypothesis doesn’t hold true for the particle size 
because the drug with the lowest molecular weight has the largest particle size while the largest 
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molecular weight has the smallest particle size. Therefore, the particle size has an inverse 
relationship to the molecular weight. This phenomenon could be caused by the clumping of the 
smaller sized drugs during the analysis of the particle radius; therefore, obscuring the results. The 
zeta potential experiment proved that the encapsulated nanoparticles have higher electro potential 
than empty nanoparticles which was the expected outcome at the beginning of the project.  
 The release study showed an overall release of 80% for NNC particles, 70% for BSA 
particles, and 50% for the IFN-γ particles. The results of the analysis of the IFN-γ samples should 
be considered unreliable because of possible issues from the ELISA assay. Therefore, if only the 
results from the BSA and NNC release studies are considered, the results align with the initial 
hypothesis. This is because NNC has the lowest molecular weight and should therefore release 
more volume quicker than a higher molecular weight drug. However, the release rate of the NNC 
from the NPs were slower than expected which could be due to NPs clumping together during the 
release. The results of the release studies were compared to standard curves for each of the drugs 
which can be seen in Figures 4-9. These results do not fully correlate to any trend with the 
molecular weights of the drugs. Therefore, more analysis should be considered. 
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Introduction 
  
 The modern-day drug delivery systems are only 60 years and have be developed and 
advanced for the human body.[1] However, there are still multiple discoveries to be made to 
improve the drug delivery inside the human body, specifically in the CNS (central nervous 
system). The main objective of this honor’s project is to encapsulate drugs with different molecular 
weights inside of chitosan-heparin based nanoparticles (Cs-Hep NPs) that are beneficial for 
various applications in the human body. For example, healing and regeneration in the CNS is one 
such application. The characterization of Cs-Hep NPs such as particle size, zeta potential, etc. were 
conducted when these drugs/proteins are encapsulated. Multiple release studies were performed to 
record the rate at which the drugs/proteins will be released from the nanoparticles. After the testing 
is complete, all the data were assessed in order to compare and summarize the differences between 
the drugs’/proteins’ release rate from the NPs with respect to molecular weight. The two specific 
objectives of this project as described below: 
1. Synthesis and characterization of the drug encapsulated Cs-Hep NPs 
The first step for completing this project was to synthesize and characterize the Cs-Hep NPs 
system. The lab had already synthesized these nanoparticles successfully in previous procedures.[2] 
Next, the encapsulation process of the drugs was completed. Three different drugs were used 
which were, interferon-γ (IFN-γ), Bovine Serum Albumin (BSA), and NNC-042090. The main 
hypothesis for this objective is that synthesized Cs-Hep NPs have the capability to encapsulate the 
previously mentioned drug molecules. Part of this process included synthesis of NPs, 
encapsulation of NPs, separation of NPs by sequential centrifugation, and freeze-drying the 
solution of the drug/protein encapsulated NPs. This produced a dry sample that made it easy to 
handle and test.  
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2. The release study of the drug encapsulated Cs-Hep NPs 
The synthesized system was assessed for a drug/protein release study using standard release 
protocol available in the lab. The drug samples from the release study were analyzed by using an 
UV spectrometer and ELISA (enzyme-linked immunosorbent assay) depending upon the 
drug/protein. The samples were drawn after an equal time interval to analyze the stepwise release. 
The hypothesis for this objective is that the whole system will provide controlled drug release. 
 Three different drugs were chosen to be analyzed during this experiment: bovine serum 
albumin (BSA), interferon gamma (IFN-γ), and NNC (NNC 05-2090). These three drugs were 
chosen because of their wide range in molecular weights; NNC having the lowest molecular 
weight, IFN-γ having the next largest, and BSA having the largest overall molecular weight. 
During this study, the correlation between the different molecular weights were assessed with the 
particle sizes, the zeta potentials, and the release study results. The hypothesis was that the trends 
will follow the correlation between the different molecular weights. 
Background 
 The beginning of the modern-day drug delivery systems began in 1950 and have been very 
successful for creating several oral and transdermal controlled chemical release mechanisms.[3] 
However, as of late (1980s-present), there have been no successful clinical trials for advanced 
chemical release systems. These failures are caused by two different types of barriers within the 
human body, biological barriers, and physicochemical barriers.[1] The physical-chemical barriers 
have been the poor water solubility of the drugs, the large molecular weight of the drugs, and the 
difficulty of controlling the drug release kinetics. The main biological barrier is getting the drug 
to be dispersed throughout the entire body instead of being localized around the release center. 
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Better control over the dispersion of the drug will give more control of the dosage and 
concentrations of drugs being delivered.[1]  
 Chitosan, which is a biodegradable, biocompatible polymer, is considered safe for wound 
dressing applications and human consumption. Chitosan-based nanoparticles are being heavily 
investigated because of its ability to deliver drugs through various applications and because of its 
chemical functional groups that can be easily modified. Another benefit of the chitosan polymer 
is that nanoparticles that are formed by chitosan typically had a positive surface charge.[4]  
 Heparin is a naturally occurring compound produced by the liver which has become the 
most common anticoagulant drug used in the world today. Heparin is paired with the chitosan to 
be the main ingredients in the synthesis of the nanoparticles in this experiment. The heparin is used 
in an excess quantity than chitosan and hence it is assumed that the NPs surface has a negative 
charge.[5] 
Experimental Methods 
Materials 
 Chitosan (Mycodev, 90 kDa, 90% DDA), heparin sodium salt from porcine intestinal 
mucosa (Sigma), glacial acetic acid (Fisher Scientific), sodium acetate trihydrate, nanowater was 
used to synthesize NPs. Drug NNC04-2090 (Torcis Bioscience) and proteins, BSA and IFN- ɣ are 
used for the experiments. Pierce 660 nm Protein Assay Reagent (450mL) and pre-diluted protein 
assay standard sets were used to analyze the BSA and NNC from the release study. ELISA kit 
(Peprotech) is used to analyze IFN-ɣ.  
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Methods 
 The procedure for this project was broken down into three main parts. First, it was 
necessary to synthesize the nanoparticles by following a procedure previously established by the 
senior student in the Leipzig Bioengineering lab.[2] The procedure entailed creating an acetate 
buffer (pH~5) and then mixing the buffer with chitosan and heparin. The chitosan mixture should 
have a concentration of 0.90 mg/mL and the heparin mixture should have a concentration of 0.95 
mg/mL. Next, the heparin and chitosan were mixed together at a ratio of 15 mL heparin to 5 mL 
chitosan. The mixture was then mixed at 800 RPM for 3 hours and left to sit overnight. The solution 
was then decanted, placed into a 50 mL C-tube, and centrifuged at 4300 RPM for 20 minutes with 
rotor JS-5.3. After the solution was centrifuged, the top 15 mL of the supernatant was removed 
and replaced by 15 mL of filtered nanowater. The solution was vortexed for 5 minutes and then 
placed back into rotor JS-5.3. The C-tubes with solution were centrifuged for 15 minutes at 4300 
RPM. The C-tubes were removed from the centrifuge and 15 mL of the supernatant was removed 
from the tubes. The mixture was vortexed for 5 minutes and was finally stored in a -20°C freezer. 
 Next, the encapsulation of the drugs in the nanoparticles took place. The diluted drug (in 
nanowater) was then added to the nanoparticle solution by using a syringe while mixing the 
nanoparticle solution at 800 RPM. This ensured maximum encapsulation of the drug in the 
nanoparticles. After being mixed for 1 hour, the solution was transferred to a 50 mL C-tube. The 
tube was then transferred to the centrifuge with the JA-25.5 rotor. The solution was centrifuged at 
8612 RPM (9000 x g) for 15 minutes. Then, the C-tube was taken out of the centrifuge, and 15 mL 
of the top supernatant was removed and replaced by 15 mL of filtered nanowater and then vortexed 
for 5 minutes.  The C-tube was placed back into the centrifuge and ran again at 8612 RPM for 15 
minutes. After complete, the top 15 mL of supernatant was removed and then the remaining 
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solution was vortexed and then stored in a -80°C freezer to be prepared for freeze drying. Freeze 
drying occurred once the solution was completely frozen. 
 The final part of the procedure consisted of a time release study of the three different types 
of drugs in the nanoparticle system. The release study took place in a Franz cell and was conducted 
over the time period of a week. Below, in Figure 1: Setup of a Franz Cell, the setup of the Franz 
cell for the release study is shown. 
 
Figure 1: Setup of a Franz Cell 
 The receptor chamber was first filled with 15 mL of Phosphate Buffered Saline (PBS) in 
order to control the pH of the solution and also act as a drying agent for the proteins to encourage 
denaturation. Next, the stir-bar was added along with the membrane, flat flange joint, and a clamp 
to secure the connection between the donor and receptor chambers. Once the connection was 
secured, 3.5 mL of the drug/PBS mixture was added to the donor chamber. Nine total release 
studies (3 drugs x 3 runs) were performed, which included three studies of each encapsulated drug 
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and a standard study for each nonencapsulated drug. For the encapsulated drug samples, the ratio 
of PBS to the encapsulated drug was 1 mL to 2.5mL in the donor chamber.   
 To start the release study, the Franz cells were placed onto a stirring plate in an incubator 
in order to simulate internal human body conditions. The stirring plate was set to 200 RPM in 
order to keep the solution moving and to prevent stagnation in the receptor chamber. A sample 
(~0.2mL) was taken from the Franz cell through the sampling port every hour, for eight hours, 
then every four hours for 32 hours, then every eight hours for 56 hours, and then finally every 
twelve hours for 72 hours. After the sample was taken, the Franz cell was replenished with an 
equal amount of fresh PBS that was added through the sampling port. Samples were taken with 
needles attached to 1 mL syringes. Each sample was clearly labeled and stored in 2 mL tubes which 
were placed in a -20°C freezer until analyzed.  
 Analysis of the BSA samples collected after the release study was conducted using Pierce 
660 nm assay (the protocol used was published by Thermo Scientific).[6] While the NNC samples 
were analyzed using the UV spectrometer at 290 nm to determine the concentration of each drug 
as time increased through each sample. First, the standard curve was determined using the known 
concentration of the drug/protein using the same respective protocols. 
 To analyze the IFN-γ samples, an ELISA protocol was followed which was published by 
PeproTech.[7] After all data was collected, it was analyzed and summarized.   
Data and Results 
The figures below show the results of the experiments performed throughout this study. 
Figure 2 relates to the particle size of the NPs. Error bars have been added to the figure to show 
the variance of all samples tested. The letters A, B, and C represent the difference between the 
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samples. If they are the same letters then there is no significance between the groups, and if the 
letters are different then the groups are significantly different. The particle size was calculated 
for the empty nanoparticles, the BSA encapsulated NPs, the NNC encapsulated NPs, and the 
IFN-γ encapsulated NPs. The particle diameter (nm) is the parameter being compared in Figure 
2.  
 Figure 3 relates to the zeta potential of the different types of NPs. The zeta potential was 
used to express the electro-kinetic charge that developed between the surface of the nanoparticles 
and the liquid surrounding the nanoparticle.[8]   Error bars have been added to the figure to show 
the variance of all samples tested for zeta potential. The letters A, B, and C represent the 
difference between the samples. If they are the same letters then there is no significance between 
the groups, and if the letters are different then the groups are significantly different. Figure 3 
shows the zeta potential in millivolts for each encapsulated nanoparticle. 
Figures 4, 5 relate to the BSA trials. Figure 4 shows the standard curve of the BSA 
encapsulated NPs. Figure 4 was used as a reference for the different absorbance values captured 
from the release study when being evaluated. Figure 5 shows the data collected from the BSA 
release study trials. Error bars are included to show the amount of variation between the data 
collected and the standard curve from Figure 4. Figure 4 shows the percentage of cumulative 
release of the BSA per hour.  
Figures 6, 7 relate to the NNC trials. Figure 6 shows the standard curve of the NNC 
encapsulated NPs. Figure 6 was used as a reference for the different absorbance values captured 
from the release study when being evaluated. Figure 7 shows the data collected from the NNC 
release study trials. Error bars are included to show the amount of variation between the data 
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collected and the standard curve from Figure 6. Figure 7 shows the percentage of cumulative 
release of the NNC per hour. 
Figures 8, 9 relate to the IFN-γ trials.  Figure 8 shows the standard curve of the IFN-γ 
encapsulated NPs. Figure 8 was used as a reference for the different absorbance values captured 
from the release study when being evaluated. Figure 9 shows the data collected from the IFN-γ 
release study trials. Error bars are included to show the amount of variation between the data 
collected and the standard curve from Figure 8. Figure 9 shows the percentage of cumulative 
release of the IFN-γ per hour. 
 
Figure 2: Particle size of the nanoparticles only (NPs) and drug/protein encapsulated NPs. 
Results are presented as a mean of 3 different trials with error bars shown as standard error. The 
letters A, B, and C relates data within 20% of each other. 
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Figure 3: Zeta potential of the nanoparticles only (NPs) and drug/protein encapsulated NPs. 
Results are presented as a mean of 3 different trials with error bars shown as standard error. The 
letters A and B relates data within 20% of each other. 
 
Figure 4: Standard curve BSA at different concentrations 
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Figure 5: Release study of BSA from NPs, results are presented as a mean of 3 different trials 
with error bar shown as standard error 
 
Figure 6: Standard curve of NNC 05-2090 at various concentrations 
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Figure 7: Release study of NNC 05-2090 from NPs, results are presented as a mean of 3 different 
trials with error bar shown as standard error 
 
Figure 8:  Standard curve of IFN-γ at various concentrations 
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Figure 9: Release study of IFN-γ from NPs, results are presented as a mean of 3 different trials. 
Error bars were not able to be added because of the inconsistency of the standard curve of IFN-γ 
 
Discussion/Analysis 
 The initial hypothesis for this study was that NPs have a capability to encapsulate 
drug/protein molecules within them. Also, it was hypothesized that these encapsulated 
drug/proteins will be released controlled over the period of time depending upon the particle size. 
We were anticipating the particle of NNC encapsulated drugs would be smaller than IFN-ϒ and 
BSA encapsulated NPs would have been the largest since molecular size of BSA is largest then 
IFN-ϒ and then drug molecule NNC. The exact molecular weights can be found in the Appendix 
in Table 1. Portions of this hypothesis were found to be correct but were not as consistent as 
previously hypothesized.  
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 The results from the particle sizing can be seen in Figure 2. The expected results were that 
the NPs would be have the smallest radius, then the NNC encapsulated particles, the IFN-γ 
encapsulated particles, and finally the BSA encapsulated particles. The actual results show that the 
smallest particles are the BSA encapsulated particles, then the empty nanoparticles, the NNC 
particles and finally the IFN-γ particles. One explanation for why this phenomenon could’ve 
happened are because the nanoparticles stuck together during the analysis. This would result in a 
skewing of the results greatly and produce the results collected. In order to analyze with more 
accurate results, a procedure for separating each nanoparticle must be followed to ensure 
measurement of each individual nanoparticle instead of nanoparticle clusters or coagulations. 
 The results of the zeta potential can be seen in Figure 3. The results from this experiment 
generally follow the hypothesis for this study. The empty nanoparticles show the lowest zeta 
potential while the other three drugs show roughly the same values for their zeta potential. These 
results show that there are negligible differences between the zeta potentials between the different 
types of drugs. However, there is a significant difference between the zeta potential values of 
empty nanoparticles versus encapsulated nanoparticles.  
 A standard curve was constructed for each of the three drugs involved in the study. The 
results can be seen in Figures 4, 6, 8. The BSA and NNC standard curves produced useful results; 
however, the IFN-γ curve produced inconclusive and varied information. An explanation for the 
inconclusive results could be poor cleaning during the ELISA protocol which could result in the 
variating results. Another possibility could be the improper formulation of the rinsing and cleaning 
agents for the ELISA protocol. Or bad reagent (too old) was supplied for the ELISA procedure. 
Each possibility could greatly affect and alter the results of the IFN-γ samples.  
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 The standard curves for BSA and NNC showed a general linear trend throughout the graph. 
BSA shows a R2 value of 0.9065 and the NNC shows a R2 value of 0.7258. Both are reasonable 
values to assume a linear trend. These standard curves were the basis of computing concentration 
of release samples drawn at different time points. 
 The average results from the three release studies are shown in Figures 5, 7, 9. The release 
study for BSA resulted in an overall release of about 70% of the encapsulated drug over the 168-
hour testing period. The release rate follows a general logarithmic trend, which meant higher initial 
release and slower release over the rest of the experiment. The release study for NNC resulted in 
an overall release of about 80% of the encapsulated drug over the 168-hour testing period. Since 
the NNC molecules are very tiny, burst releases were expected in the first half of the trials; 
however, none of these properties were observed from the collected data. The release rate also 
follows a logarithmic trend, similar to the BSA trend. The release study for IFN-γ resulted in an 
overall release of only 50% of the encapsulated drug over the 168-hour testing period. These results 
seem skewed, since IFN-γ has the lowest molecular weight of any of the drugs, therefore it should 
have the most drug released. However, the trend of the release rate follows the same logarithmic 
trend as the other two drugs. Some error likely occurred with this assay during analysis and 
unfortunately could not be retested because of time constraints.  
 Error bars were used in the graphs in order to show the variance between each of the three 
trials for each of the drugs and each of the standards that were calculated. Due to a lack of time, 
no additional analysis or trials were able to be completed to verify/expand on the results gathered 
in this report. To improve accuracy in the future, additional analysis and trials should be 
considered. 
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Conclusions/Recommendations 
 The initial hypothesis for this study was that there was a constant relationship between the 
release amount and release time of the encapsulated nanoparticles depending on the drug of 
choice’s molecular weight. This theory was not constant for the whole project. As seen in Figure 
2, the particle size of each encapsulated drug does not correlate to the molecular weight of the 
drugs. This is believed to be inconsistent because of the common case of nanoparticles sticking 
together, causing improper measurements of particle radii. The results of the zeta potential for 
different drugs can be seen in Figure 3. The zeta potential followed the trend of the hypothesis 
and correlates from the lowest molecular weight drug to the highest molecular weight drug. 
 The data from the release studies were compared to standard curves for each drug. These 
results can be seen in Figures 4-9. Error bars are shown on the BSA and NNC release study graphs 
to show the variance from the standard curves. The BSA sample released 70% of its drug in the 
168-hour time period and the NNC sample released around 80% of its drug in the same amount of 
time. These results were expected because NNC has the lowest molecular weight; however, the 
rate at which the NNC was released was a lot slower than anticipated. The IFN-γ release studies 
were not able to be compared to a standard because of how poorly the standard curve turned out 
from the ELISA protocol. Therefore, no definitive information could be obtained from this study. 
 Recommendations for this project include using fresh and sealed assay agent for the ELISA 
protocol in order to ensure correct analyzation of IFN-γ. For future experiments that are similar to 
this one, a different selection of drugs could be beneficial. To ensure the accuracy of measuring 
particle size, the nanoparticles should be vortexed intensely in order to attempt to break up clusters 
of nanoparticles before analysis. Also, having more than three Franz cells when testing the release 
studies would help ensure accuracy and would save a lot of time.   
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Appendices 
Table 1: Molecular weights of all three drugs used in the experiments 
 
 
66.5 kDa 16.9 kDa 451 g/mol
Highest Lowest
Drug Molecular Weights
NNC 05-2090Bovine serum albumin
BSA NNCIFN-γ
Interferon Gamma
